Mangafodipir

Mangafodipir

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy cat.	Not to be used
Legal status	?
Routes	Intravenous infusion
Pharmacokinetic data
Bioavailability	NA
Protein binding	27% (manganese) Negligible (DPDP)
Half-life	20 minutes (manganese) 50 minutes (DPDP)
Excretion	Renal and fecal (manganese) Renal (DPDP)
Identifiers
CAS number	119797-12-5 Y
ATC code	V08CA05
PubChem	CID 3086672
ChemSpider	2343239 Y
UNII	N02W67RKJS N
ChEMBL	CHEMBL1628242 N
Chemical data
Formula	C22H28MnN4O14P2
Mol. mass	689.362 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C22H32N4O14P2.Mn/c1-13-21(31)17(15(5-23-13)11-39-41(33,34)35)7-25(9-19(27)28)3-4-26(10-20(29)30)8-18-16(12-40-42(36,37)38)6-24-14(2)22(18)32;/h5-6,31-32H,3-4,7-12H2,1-2H3,(H,27,28)(H,29,30)(H2,33,34,35)(H2,36,37,38);/q;+2 Y Key:QDQFSBKXQQZVTB-UHFFFAOYSA-N Y
N(what is this?)  (verify)

Mangafodipir (sold under the brand name Teslascan as mangafodipir trisodium) is a contrast agent delivered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver. It has two parts, paramagnetic manganese (II) ions and the chelating agent fodipir (dipyridoxyl diphosphate, DPDP). Normal liver tissue absorbs the manganese more than abnormal or cancerous tissue. The manganese shortens the longitudinal relaxation time (T1), making the normal tissue appear brighter in MRIs. This enhanced contrast allows lesions to be more easily identified.

References

• Teslascan.com
• MedlinePlus data sheet
• Medsafe data sheet

Iodinated,
Water insoluble

Ethyl esters of iodised fatty acids • Iopydol • Propyliodone • Iofendylate • Lipiodol

Non-iodinated

Barium sulfate^#

MRI

Paramagnetic	Gadolinium-based: Gadobenic acid • Gadobutrol • Gadodiamide • Gadofosveset • Gadolinium • Gadopentetic acid • Gadoteric acid • Gadoteridol • Gadoversetamide • Gadoxetic acid Other: Ferric ammonium citrate • Mangafodipir
Superparamagnetic	Ferumoxsil • Ferristene • Iron oxide, nanoparticles
Other	Perflubron

Ultrasound

Microspheres of human albumin • Microparticles of galactose • Perflenapent • Microspheres of phospholipids • Sulfur hexafluoride

^#WHO-EM. ^‡Withdrawn from market. Clinical trials: ^†Phase III. ^§Never to phase III